NewsfeedFollowed Companies

Amgen's Competitors, Revenue, Number of Employees, Funding and Acquisitions

Amgen discovers, develops, manufactures and delivers human therapeutics for patients suffering from serious illnesses.

Am... Read more

Based on data from Amgen's latest SEC filings

Annual Revenue

Based on data from Amgen's latest SEC filings

Employees

Robert A. Bradway's photo - Chairman & CEO of Amgen

Chairman & CEO

Robert A. Bradway

CEO Approval Rating

72/100

OVERVIEW

Founded:

1980

Headquarters:

Thousand OaksCalifornia

Status:

PublicIndependent Company of NASDAQAMGN

Industry Sector:

Biotechnology

SIC Code:

2836NAICS listing »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Sanofi a competitor of Amgen?

I don't know

Trending News for Amgen and Amgen's Competitors

November 15, 2019

BioPortfolio

Amgen and The Duke Clinical Research Institute Initiate First LargeScale Registry to Evaluate RealWorld Lipid Management and the Effectiveness of PCSK9 Inhibitors

THOUSAND OAKS Calif.ÂNov. 15 2019ÂPRNewswire &8212;ÂAmgenÂNASDAQAMGN in collaboration with theÂDuke C... See more »

November 16, 2019

Reuters

UPDATE 2-Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on conditi... See more »

November 15, 2019

Reuters

UPDATE 2-Novartis sickle-cell drug gets U.S. FDA approval

Novartis AG on Friday won U.S. approval for its experimental sickle cell disease drug, Adakveo, makin... See more »

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

AbbVie is the top competitor of Amgen. AbbVie was founded in 2012, and its headquarters is in North Chicago, Illinois. AbbVie is in the Pharmaceuticals field. AbbVie has 10,800 more employees than Amgen.

Celgene is seen as one of Amgen's top competitors. Celgene was founded in Summit, New Jersey} in 1986. Like Amgen, Celgene also works within the Biotechnology industry. Compared to Amgen, Celgene generates $7.5B less revenue.

Coherus BioSciences is Amgen's #3 rival. Coherus BioSciences's headquarters is in Redwood City, California, and was founded in 2010. Like Amgen, Coherus BioSciences also competes in the Biotechnology sector. Coherus BioSciences generates 1.00% of Amgen's revenue.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

Robert A. Bradway

Chairman & CEO

- -
19,200
$19M
$23.4B
1

Richard A. Gonzalez

Chairman & CEO

76/100
30,000
- -
$32.9B
2

Mark J. Alles

Chairman & CEO

70/100
8,852
- -
$17B
3

Denny Lanfear

Chairman & CEO

78/100
152
$244.8M
$232.2M
4

Heather Bresch

CEO

65/100
35,000
$7.9B
$11.4B
5

Jörg Kneubühler

CEO

70/100
4,944
- -
$3.3B
6

Paul Hudson

CEO

64/100
106,859
- -
$41.8B
7

David A. Ricks

Chairman & CEO

70/100
38,680
- -
$24.9B
8

Kaare Schultz

President & CEO

68/100
42,535
$5.5B
$17.5B
9

Albert Bourla

CEO

76/100
92,400
- -
$53B
10

Vasant Narasimhan

CEO

71/100
118,393
- -
$50.3B
The top 10 competitors in Amgen's competitive set are AbbVie, Celgene, Coherus BioSciences, Mylan, Galenica, Sanofi, Eli Lilly, TEVA Pharmaceuticals, Pfizer and Novartis. Together they have raised over 13.7B between their estimated 481.9K employees. Amgen has 19,200 employees and is ranked 8th among it's top 10 competitors. The top 10 competitors average 45,183.

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$23.4B

Amgen's revenue is the ranked 6th among it's top 10 competitors. The top 10 competitors average 25.1B. Over the last four quarters, Amgen's revenue has decreased by 7.9%. Specifically, in Q3 2019's revenue was $5.7B; in Q2 2019, it was $5.9B; in Q1 2019, it was $5.6B; in Q4 2018, Amgen's revenue was $6.2B.

Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Nuevolution A/S

May 2019

Source »
$166.8M
Nuevolution develops small molecule drug therapeutics for the treatment of cancer and chronic inflammatory diseases.
Dezima Pharma BV

Sep 2015

Source »
$300M
Dezima Pharma is engaged in the development of novel drugs to treat cardiovascular disease related to dyslipidemia.
Onyx Pharmaceuticals, Inc.

Aug 2013

Source »
$9.7B
Onyx develops and commercializes therapies for the treatment of cancer.
DGI Resolution, Inc.

Dec 2012

Source »
undisclosed
DGI Resolution discovers genetic risk factors for diseases from cardiovascular disease to cancer.
Mustafa Nevzat İlaç Sanayii A.Ş.

Apr 2012

Source »
$700M
-

These are all the companies that Amgen has acquired. Amgen has acquired 12 companies and its latest acquisition was Nuevolution A/S in May 2019. Nuevolution develops small molecule drug therapeutics for the treatment of cancer and chronic inflammatory diseases.

Amgen Funding History

Since Amgen was founded in 1980, it has participated in 1 round of funding. In total Amgen has raised $19.0M. Amgen's funding round was on Apr 1980 for a total of $19.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
Apr 1980
$19M
-

Total Funding: $19M

Since Amgen was founded in 1980, it has participated in 1 round of funding. In total Amgen has raised $19.0M. Amgen's funding round was on Apr 1980 for a total of $19.0M

Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

BeiGene is a biopharmaceutical company that focuses on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer.
$2.7B
Oct 30, 2019
Equity
Feb 03, 2016
Oxford Nanopore develops and commercializes nanopore-based DNA, RNA and protein molecule sensing systems for clinical research companies.
$66M
Oct 17, 2018
Equity
-
Arrowhead focuses on developing medicines that treat intractable diseases by using ribonucleic acid interference mechanism.
$10M
Aug 02, 2018
Unattributed
-
Science 37 develops a cloud-based mobile research platform that allows pharmaceutical companies to conduct clinical trials in patient homes.
$130M
Jun 06, 2018
Series D
-
Precision develops a genome editing platform that provides immuno-oncology therapeutics for the treatment of cancer.
$88.1M
May 24, 2018
Series B
Mar 27, 2019

These are all the companies that Amgen has invested in. Amgen has invested 12 companies and its latest investment was Nuevolution A/S in May 2019. Nuevolution develops small molecule drug therapeutics for the treatment of cancer and chronic inflammatory diseases.

Amgen News

November 11, 2019San Fernando Valley Business Journal

Amgen's Buy Mode

Amgen Inc. expands by investing $2.7 billion in Chinese company and buying a psoriasis drug for $13.4... See more »
November 9, 2019BioPortfolio

. Amgen Expands China Presence Cancer R&D with $2.7B BeiGeneUSA Collaboration httpow.lyOlsW50wZSSnÂpic.twitter.comdlWmbm9Bs1

. Amgen Expands China Presence Cancer R&D with $2.7B BeiGeneUSA Collaboration httpow.lyOlsW50wZSSn pi... See more »
November 9, 2019MarketScreener

Biomarker Testing in Personalized Cancer Medicine

(marketscreener.com) Oncology has traditionally treated patients through combinations of surgery, che... See more »
November 9, 2019MarketScreener

Staff Shine Bright at "Light the Night"

(marketscreener.com) Every year, thousands of Amgen staff around the world donate their time, money a... See more »
November 8, 2019The Business Journals: Tampa Bay

Meet Amgen, a 2019 One Tampa Bay honoree

Amgen is an American multinational biopharmaceutical company and one of this year's One Tampa Bay hon... See more »
November 8, 2019FiercePharma

FiercePharmaAsia-Amgen-BeiGene $2.7B tie-up; AZ's China projects; controversial Alzheimer's drug

Amgen is taking a 20.5% stake in BeiGene, which will help the Big Biotech develop cancer drugs in Chi... See more »
November 7, 2019MarketScreener

To Present At The 28th Annual Credit Suisse Healthcare Conference

(marketscreener.com) THOUSAND OAKS, Calif., Nov. 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will pre... See more »

Amgen Press Releases

September 24, 2019PR Newswire

Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia

THOUSAND OAKS, Calif., Sept. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the re... See more »
September 18, 2019PR Newswire

Verantos Announces Publication of a Real-World Evidence Collaborative Study with Amgen

PALO ALTO, Calif., Sept. 18, 2019 /PRNewswire/ -- Verantos, the market leader in regulatory-grade rea... See more »
September 9, 2019StreetInsider

Toronto Innovation Acceleration Partners Announces Strategic Partnership with Amgen

Toronto, Ontario, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP f... See more »
August 8, 2019PR Newswire

OneOncology Is Early Adopter of Biosimilars in U.S.

NASHVILLE, Tenn., Aug. 8, 2019 /PRNewswire/ -- OneOncology announced today that its partner practices... See more »
April 17, 2019PR Newswire

CDC Foundation, Amgen Announce Program to Increase Awareness and Knowledge of Cardiovascular Diseases Globally

ATLANTA, April 17, 2019 /PRNewswire/ -- According to the World Health Organization (WHO), cardiovascu... See more »
March 8, 2019centralcharts

Amgen To Present At The Cowen and Company 39th Annual Healthcare Conference

Amgen (NASDAQ:AMGN) will present at the Cowen and Company 39th Annual Healthcare Conference at 9:20 a... See more »
February 7, 2019PR-Inside

Molecular Partners Reports Key Financials for FY 2018 and Corporate

(PR-inside.com) Research & Development: MP0310: Molecular Partners and Amgen announced strategic coll... See more »

Amgen Videos

June 13, 2019Amgen Youtube Channel

"The Digital Cell Biology Revolution" on YOUTUBE

See more »
May 29, 2019Amgen Youtube Channel

"Next-Generation BioManufacturing" on YOUTUBE

See more »
October 12, 2018Amgen Youtube Channel

"Big Impact in Bio: Improving the Science of Science" on YOUTUBE

See more »
June 22, 2018Amgen Youtube Channel

"Learn what's happening at Amgen Rhode Island" on YOUTUBE

See more »
March 2, 2018Amgen Youtube Channel

"Using Human Genetics to Discover New Medicines | Amgen Science: The Value of Rare Variants" on YOUTUBE

See more »
January 29, 2018Amgen Youtube Channel

"Students Describe the Amgen Scholars Program as Inspiring and Unforgettable" on YOUTUBE

See more »
December 20, 2017Amgen Youtube Channel

"Young Scientists Share Their Thoughts on the Amgen Biotech Experience in Singapore" on YOUTUBE

See more »

Social Statistics

Headquarters

One Amgen Center Drive

Thousand Oaks, California91320

805-447-1000

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Amgen discovers, develops, manufactures and delivers human therapeutics for patients suffering from serious illnesses. Amgen was founded in 1980. Amgen's headquarters is located in Thousand Oaks, California, USA 91320. It has raised 19.0M in 1 round. ...

CEO

Amgen's Chairman & CEO, Robert A. Bradway, currently has an approval rating of 72%. Amgen's primary competitors are AbbVie, Celgene & Coherus BioSciences.

Website

amgen.com

Frequently Asked Questions about Amgen

  1. When was Amgen founded?

    Amgen was founded in 1980

  2. Who is Amgen's CEO?

    Amgen's CEO is Robert A. Bradway

  3. How much revenue does Amgen generate?

    Amgen generates $23.4B in revenue

  4. How much funding does Amgen have?

    Amgen has historically raised $19M in funding

  5. Where is Amgen's headquarters?

    Amgen's headquarters is in Thousand Oaks California, USA

  1. How many employees does Amgen have?

    Amgen has 19,200 employees

  2. What sector does Amgen operate in?

    Amgen is in Biotechnology

  3. Who are Amgen's competitors?

    Amgen's top competitors are AbbVie, Celgene, Coherus BioSciences

  4. Who has Amgen invested in?

    Amgen's has invested in companies such as BeiGene, Oxford Nanopore, Arrowhead
Stay up-to-date with the latest news on Amgen